An Open‐Label, Dose‐Escalation Study to Assess the Safety and Efficacy of IL‐22 Agonist F‐652 in Patients With Alcohol‐associated Hepatitis-Reference-Cited by-同舟云学术

An Open‐Label, Dose‐Escalation Study to Assess the Safety and Efficacy of IL‐22 Agonist F‐652 in Patients With Alcohol‐associated Hepatitis

Published:2020-04-27 Issue:2 Volume:72 Page:441-453
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Arab Juan P.¹²^ORCID,Sehrawat Tejasav S.¹,Simonetto Douglas A.¹,Verma Vikas K.¹,Feng Dechun³,Tang Tom⁴,Dreyer Kevin⁴,Yan Xiaoqiang⁴,Daley William L.⁴,Sanyal Arun⁵,Chalasani Naga⁶,Radaeva Svetlana⁷,Yang Liu⁸,Vargas Hugo⁹,Ibacache Mauricio¹⁰,Gao Bin³,Gores Gregory J.¹,Malhi Harmeet¹^ORCID,Kamath Patrick S.¹,Shah Vijay H.¹^ORCID

Affiliation:

1. Division of Gastroenterology and Hepatology Mayo Clinic Rochester MN

2. Department of Gastroenterology, School of Medicine Pontifical Catholic University of Chile Santiago Chile

3. Laboratory of Liver Diseases National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health Bethesda MD

4. Generon Corporation Ltd. Shanghai China

5. Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine Virginia Commonwealth University Richmond VA

6. Department of Internal Medicine Indiana University School of Medicine Indianapolis IN

7. National Institute on Alcohol Abuse and Alcoholism Bethesda MD

8. Division of Gastroenterology and Hepatology Mayo Clinic Jacksonville FL

9. Division of Gastroenterology and Hepatology Mayo Clinic Scottsdale AZ

10. Division of Anesthesiology, School of Medicine Pontifical Catholic University of Chile Santiago Chile

Funder

Fondo Nacional de Desarrollo Científico y Tecnológico

National Institutes of Health

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.31046

Reference44 articles.

1. Alcoholic Liver Disease-Related Mortality in the United States: 1980–2003

2. Alcoholic Liver Disease in Asia, Europe, and North America

3. Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK

4. Alcoholic Hepatitis

5. Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets

Cited by 131 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel insight into MDA-7/IL-24: A potent therapeutic target for autoimmune and inflammatory diseases;Clinical Immunology;2024-09

2. The Impact of Liver Failure on the Immune System;International Journal of Molecular Sciences;2024-09-01

3. Role of Neutrophils in the Development of Steatotic Liver Disease;Seminars in Liver Disease;2024-08-08

4. Role of the type 3 cytokines IL-17 and IL-22 in modulating metabolic dysfunction-associated steatotic liver disease;Frontiers in Immunology;2024-08-02

5. Lipid-encapsulated mRNA encoding an extended serum half-life interleukin-22 ameliorates metabolic disease in mice;Molecular Metabolism;2024-08